ANDROGEN RECEPTORS AS A FACTOR OF PROGNOSIS IN VARIOUS MOLECULAR-BIOLOGICAL SUBTYPES OF BREAST CANCER
https://doi.org/10.21294/1814-4861-2017-16-3-40-45
Abstract
In the literature there has been increased interest in the study of androgenetic receptors (AR) in different molecular subtypes of breast cancer (BC) but we haven’t found consensus about the role of levels of androgens and their metabolites in samples of biological fluids for the development of breast cancer. Determination of the level of androgenetic receptors in the tumor in patients with breast cancer is very relevant and promising direction in the study of the prognosis of the disease and the search for new complementary approaches to endocrine therapy of breast cancer, especially when basal-like molecular subtype.
About the Authors
D. A. Ryabchikov
N.N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
Russian Federation
MD, PhD, Senior Researcher, Surgical Department of Breast Cancer № 5
24, Kashirskoe shosse, 115478-Moscow
I. K. Vorotnikov
N.N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
Russian Federation
MD, DSc, Professor, Head of Surgical Department of Breast Cancer № 5
24, Kashirskoe shosse, 115478-Moscow
N. A. Kozlov
N.N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
Russian Federation
MD, PhD, Physician, Department of Pathology
24, Kashirskoe shosse, 115478-Moscow
SPIN-code: 1847-6530
N. V. Chkhikvadze
N.N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
Russian Federation
MD, PhD, Physician, Surgical Department of Breast Cancer № 5
24, Kashirskoe shosse, 115478-Moscow
References
1. Axel’ E.M. Malignant formations of the breast: The state of cancer care, morbidity and mortality. Mammalogy. 2006; 1: 9–15. [in Russian]
2. Davydov M.I., Axel’ E.M. Statistics of malignant neoplasms in Russia and CIS countries in 2005. Bulletin N.N. Blokhin RONC RAMS. 2010; 2 (21). Suppl. 1 [in Russian]
3. Safarpour D., Tavassoli F.A. A Targetable Androgen Receptor– Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. Arch Pathol Lab Med. 2015; 139 (5): 612–7. doi: 10.5858/ arpa.2014-0122-RA.
4. Krylov A.Yu., Krylov Yu.V. Androgens and breast cancer (literature review). Bulletin of the Vitebsk State Medical Institute. 2015; 14 (5): 5–15. [in Russian]
5. Brys M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit. 2000; 6 (2): 433–438.
6. Liao D.J., Dickson R.B. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002; 80 (2): 175–189.
7. Isola J.J. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993; 170 (1): 31–35.
8. Hu R., Dawood S., Holmes M.D., Collins L.C., Schnitt S.J., Cole K., Marotti J.D., Hankinson S.E.,Colditz G.A., Tamimi R.M. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011; 17 (7): 1867–74. doi: 10.1158/1078-0432.CCR-10-2021.
9. Moinfar F., Okcu M., Tsybrovskyy O., Regitnig P., Lax S.F., Weybora W., Ratschek M., Tavassoli F.A., Denk H. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer. 2003; 98 (4): 703–711.
10. Ogawa Y., Hai E., Matsumoto K., Ikeda K., Tokunaga S., Nagahara H., Sakurai K., Inoue T., Nishiguchi Y. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2001. 13 (5). P. 431–5. doi: 10.1007/ s10147-008-0770-6.
11. Tang D., Xu S., Zhang Q., Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol. 2012; 29 (2): 526–533. doi: 10.1007/s12032- 011-9948-2.
12. Federici C., Petrucci F., Caimi S., Cesolini A., Logozzi M., Borghi M., D’Ilio S., Lugini L., Violante N., Azzarito T., Majorani C., Brambilla D., Fais S. Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin. PLoS ONE. 2014; 9 (2): e88193. doi: 10.1371/journal.pone.0088193
13. Panet-Raymond V., Gottlieb B., Beitel L.K., Pinsky L., Trifiro M.A. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol. 2000; 167 (1): 139–150.
14. Tokunaga E., Hisamatsu Y., Taketani K., Yamashita N., Akiyoshi S., Okada S., Tanaka K., Saeki H., Oki E., Aishima S., Oda Y., Morita M., Maehara Y. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer. Cancer Med. 2013; 6 (2): 763–73. doi: 10.1002/cam4.138.
Review
For citations:
Ryabchikov D.A., Vorotnikov I.K., Kozlov N.A., Chkhikvadze N.V. ANDROGEN RECEPTORS AS A FACTOR OF PROGNOSIS IN VARIOUS MOLECULAR-BIOLOGICAL SUBTYPES OF BREAST CANCER. Siberian journal of oncology. 2017;16(3):40-45. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-3-40-45
Views:
1518
Email this article 
